高级搜索
任梦薇, 薛学敏, 刘鹏. Merkel细胞癌单中心治疗及转归[J]. 肿瘤防治研究, 2023, 50(4): 364-369. DOI: 10.3971/j.issn.1000-8578.2023.22.1101
引用本文: 任梦薇, 薛学敏, 刘鹏. Merkel细胞癌单中心治疗及转归[J]. 肿瘤防治研究, 2023, 50(4): 364-369. DOI: 10.3971/j.issn.1000-8578.2023.22.1101
REN Mengwei, XUE Xuemin, LIU Peng. Treatment and Outcome of Merkel Cell Carcinoma in A Single Center[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 364-369. DOI: 10.3971/j.issn.1000-8578.2023.22.1101
Citation: REN Mengwei, XUE Xuemin, LIU Peng. Treatment and Outcome of Merkel Cell Carcinoma in A Single Center[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 364-369. DOI: 10.3971/j.issn.1000-8578.2023.22.1101

Merkel细胞癌单中心治疗及转归

Treatment and Outcome of Merkel Cell Carcinoma in A Single Center

  • 摘要:
    目的 探讨Merkel细胞癌患者的临床特征、治疗方法及转归特点。
    方法 回顾性分析2017年以来中国医学科学院肿瘤医院收治的6例Merkel细胞癌患者的临床表现、辅助检查、诊治经过及随访资料。
    结果 6例Merkel细胞癌患者中男4例、女2例,中位发病年龄66岁(57~76岁)。6例患者均以出现皮肤肿物起病,临床分期:Ⅰ期3例、Ⅲ期1例、Ⅳ期2例。单纯手术治疗2例、手术联合放疗和(或)化疗3例,免疫治疗联合化疗1例。截至随访时间,4例疾病无进展,1例因疾病进展死亡,1例仍规律治疗中。
    结论 局限期Merkel细胞癌以手术、放疗为主,转移性Merkel细胞癌多需应用全身治疗,一线选择靶向程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)途径的免疫检查点抑制剂可取得较好的治疗效果。

     

    Abstract:
    Objective To investigate the clinical features, treatment, and outcome characteristics of patients with Merkel cell carcinoma.
    Methods The clinical manifestations, laboratory tests, diagnosis and treatment, and follow-up data of six patients with Merkel cell carcinoma were retrospectively analyzed.
    Results Among the six patients with Merkel cell carcinoma, four were males and two were females, with a median age of 66 years old (57-76 years old). All six patients presented with skin swelling, and the clinical stages were as follows: stageⅠ in three patients, stage Ⅲ in one patient, and stage IV in two patients. Two patients were treated with surgery alone, three patients with surgery combined with radiotherapy and/or chemotherapy, and one patient with immunotherapy combined with chemotherapy. Until the follow-up time, four patients had no disease progression, one patient died because of disease progression, and one patient remained under treatment.
    Conclusion Limited-stage Merkel cell carcinoma is primarily treated with surgery and radiotherapy, meanwhile, metastatic Merkel cell carcinoma needs systemic therapy, and first-line immune checkpoint inhibitors targeting PD-1/ PD-L1 pathway can achieve better therapeutic results.

     

/

返回文章
返回